Aurenar
Latest round
- Seed
Last raised
- Jun 2026
Total raised
- $5.7M
Investors
- 4
About Aurenar
Based in the US, Aurenar, Inc is a neurotechnology company dedicated to developing innovative solutions that enhance patient care in intensive care settings through advanced neuromodulation techniques., founded by Dr. Eric Leuthardt (CEO), Dr. Anna Huguenard (CTO), Anna Huguenard and Jeff Dunn focuses on neurotechnology aimed at treating inflammation through a unique ear-worn device. In June 2026, Aurenar, Inc. Aurenar, Inc specializes in innovative neurotechnology designed to address inflammation, a critical factor in complications and costs within Intensive Care Units (ICUs). Their core product is an ear-worn device that utilizes imperceptible and non-invasive stimulation to activate a nerve located in the ear, enhancing the body’s natural control of inflammation. This device aims to improve patient outcomes and reduce hospital lengths of stay, ultimately lowering the cost of care for high-cost patients in critical settings. The primary beneficiaries of Aurenar’s offerings include healthcare providers in the ICU environment, with potential applications extending to hospitals and specialized medical institutions across North America and Europe, where high-volume, high-cost patient care is prevalent. Aurenar’s revenue model is structured around transactions with healthcare institutions and providers who integrate their wearable neurostimulation device into patient care protocols. These transactions may occur through direct sales to hospitals or partnerships with medical device distributors, facilitating broader access to their technology. The company emphasizes the value proposition of its flagship product, which is positioned to deliver significant cost savings and improved clinical outcomes, thus making it an attractive offering for healthcare systems facing financial pressures. The pricing structure is designed to reflect the operational benefits derived from its implementation, aligning with the financial objectives of healthcare providers seeking to optimize resource utilization and enhance patient care.S. Food and Drug Administration. Aurenar plans to expand its product offerings and market presence, particularly targeting healthcare institutions across North America and Europe, where demand for innovative solutions in patient care is high.
Who invested in Aurenar
4 investors across 1 round
See all investors in Aurenar
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jun 30, 2026
Amount
$5.7M
Investors
Questions about Aurenar
Who invested in Aurenar?
Aurenar has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Aurenar raised?
Aurenar has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Aurenar last raise money?
Aurenar's most recent round on record is a Seed, in Jun 2026.
What does Aurenar do?
Based in the US, Aurenar, Inc is a neurotechnology company dedicated to developing innovative solutions that enhance patient care in intensive care settings through advanced neuromodulation techniques.
Where is Aurenar headquartered?
Aurenar is headquartered in Saint Louis, US.
Which VCs invest in companies like Aurenar?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back medical devices & equipment companies at Aurenar's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Seed
Raising like Aurenar? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.